

October 09, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
BSE Scrip Code: 531349

Sub: Compliance under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please find enclosed herewith newspaper copies regarding notice intimating the investors about the opening of a Special Window for Transfer and Dematerialization of physical shares, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, published on October 09, 2026, in the following newspapers:

- Financial Express; and
- Desh Sewak (Punjabi)

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

**ANKIT
JAIN**  Digitally signed by
ANKIT JAIN
Date: 2026.10.09
15:01:39 +05'30'

Ankit Jain
General Manager- Legal & Company Secretary

India backs US-led initiative against 'excess capacity'

FE BUREAU
New Delhi, October 8

INDIA HAS JOINED a US-led initiative to tackle “structural excess capacity” in manufacturing, a move that could draw scrutiny given its own rapid expansion in sectors such as solar modules, steel and petrochemicals, some of which are already under the Trump administration’s trade lens.

The initiative seeks to address concerns that excess manufacturing capacity can distort global trade by fuelling overproduction, depressing prices and displacing domestic industries through state-subsidised dumping.

India is among 15 economies that have signed a joint ministerial statement unveiled by the US Trade Representative (USTR) to address structural excess capacity and production.

The initiative will initially cover automobiles and electric vehicles, batteries, chemicals, foundational semiconductors and solar panels, with participating economies setting up sectoral platforms to exchange information and explore coordinated action.

The move comes nearly seven months after USTR launched a Section 301 investigation into structural excess capacity across 16 economies, including India, the European Union, Japan, Mexico and South Korea. The five are now both subjects of the probe and signatories to the new initiative.

USTR has raised concerns about expanding capacity and potential export-driven oversupply in solar modules, steel and petrochemicals, citing Indian solar-module capacity as nearly three times annual domestic demand. The deadline for its final Section 301 findings is March 11, 2027. The joint statement calls for countries to eliminate structural excess capacity, including by ending non-market policies and practices that distort markets. It says excess capacity can lead to overproduction, price distortions, concentration of production and weaker competition.

The Global Trade Research Initiative (GTRI) founder Ajay Srivastava said India was now “joining Washington in tackling the very issue for which its own manufacturing is under American investigation”.

US-LED PUSH

- 15 economies have signed joint ministerial statement
- Initial focus: autos & EVs, batteries, chemicals, foundational semiconductors
- Initiative aims to curb overproduction, price distortions, state-subsidised dumping
- Comes amid Section 301 probe by US into excess capacity across 16 economies
- India is both under probe and signatory to new initiative



WTO raises global trade forecast for 2026 to 3.9%

FE BUREAU
New Delhi, October 8

THE WEST ASIA conflict has disrupted energy supplies and shipping routes but has so far failed to derail global merchandise trade, prompting the World Trade Organization (WTO) to sharply raise its forecast for 2026 trade growth to 3.9% from 1.9% in its March outlook.

The latest Global Trade Outlook and Statistics, released Thursday, marks a significant turnaround from the WTO’s earlier assessment. The organisation had cut its 2026 merchandise trade forecast to 1.9% in March as the conflict raised the prospect of an oil shock and wider disruption. It now expects global merchandise trade volume to grow another 4.1% in 2027.

The stronger outlook follows 3.5% growth in merchandise trade in the first half of 2026, despite the conflict. Supply chains adapted by switching suppliers and rerouting trade through alternative ports and corridors. West Asia crude oil exports fell about 24% and LNG exports 47% during the period, but increased shipments from other suppliers limited the decline in global exports to around 6% for crude and 1% for LNG. Global container throughput rose 3.9% through July.



The biggest support came from the boom in artificial intelligence investment. Semiconductors, servers and other AI-enabling goods accounted for 47% of global merchandise trade growth in the first half, with trade in these products rising 67% year-on-year.

The conflict has had a more visible impact on services trade.

The WTO cut its 2026 forecast for commercial services trade growth to 3.3% from 4.8%, before projecting a rebound to 6.4% in 2027. Transport services have been hit by rerouted shipping and higher freight costs, while international travel has weakened.

International tourist arrivals fell 0.8% year-on-year in the second quarter and were only 0.4% higher in the first half. In contrast, digitally delivered services remained resilient, with computer services exports rising 1.8% in the first quarter and an estimated 12% in the second.

SC orders pharma marketing review

MANU KAUSHIK
New Delhi, October 8

THE SUPREME COURT has directed the Centre to set up a panel to review unethical pharma marketing practices and assess whether the existing regulatory framework is adequate. The panel will also examine mechanisms for monitoring, transparency and enforcement.

The move comes after the court found that the existing framework warranted closer examination, particularly its effectiveness in preventing unethical practices. The panel will identify gaps and recommend an appropriate statutory or regulatory framework to the government.

The government has two weeks to constitute the panel. It will give petitioners, intervenors and other stakeholders a reasonable opportunity to submit their views and concerns. The panel may also seek inputs from technical, professional and domain experts.

It has been given two months from its first meeting to complete the exercise and submit its recommendations. The government will then consider the recommendations and take a decision at the earliest. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 will continue to govern pharma marketing practices in the interim, according to the government’s submission. While the court did not make the UCPMP statutory, it said choosing the appropriate statutory or regulatory framework falls primarily within the central government’s domain.

The order noted that the government had already held consultations with industry bodies.

Prices of 110 anti-cancer drugs to fall sharply

MANU KAUSHIK
New Delhi, October 8

THE GOVERNMENT IS set to cap trade margins at 30% on 110 non-scheduled anti-cancer drugs, including 35 patented medicines, sources in the Department of Pharmaceuticals (DoP) told FE. The move could make these high-priced medicines more affordable to consumers.

The government estimates that the cap could cut the maximum retail prices (MRPs) of these drugs by up to 70% and save patients an estimated ₹2,500 crore annually. The tighter margin ceiling is also likely to pressure retailers, hospital chains and pharma companies that earn higher margins on these drugs.

“These non-scheduled drugs were not under any caps before. A committee under the Director General of Health Services (DGHS) will examine and finalise the list of medicines to be covered. The move will cover generics, patented, imported and locally-produced drugs,” the DoP official said.

Non-scheduled drugs are medicines whose prices are not directly fixed by the government. Scheduled drugs, in contrast, are subject to government-controlled price limits under the Drugs (Prices Control) Order, 2013 (DPCO). The scheduled list is based on medicines included in the National List of Essential Medicines (NLEM).

According to the official, the government plans to complete the exercise within 10 days.

BIG RELIEF



■ List includes 35 patented medicines

■ Govt estimates MRPs could fall by up to

70%

■ Patients could save an estimated ₹2,500 cr annually

■ Cap will cover generic, patented, imported, locally produced drugs

“There’s already a 16% cap on trade margins on the scheduled drugs across the board. The move is likely to affect retailers, hospital chains and pharma companies, especially those who work on high margins,” he said.

Under the existing framework, the scheduled drugs are subject to government-regulated trade margins when their ceiling prices are fixed.

GLP-1 mkt value jumps 72% on new products

MANU KAUSHIK
New Delhi, October 8

THE ANTI-OBESITY drug GLP-1 market grew 72% in sales value year-on-year in September 2026, even as the number of units sold fell 10%, according to the latest data from healthcare research firm Pharmarack. The growth was driven largely by new products, while prices remained broadly unchanged. The sharp divergence between value and volume growth points to a significant shift in the market’s composition.

According to the report, the broader anti-obesity drug market stood at ₹287.9 crore in September, up 5.8% from ₹272.1 crore in August. On a moving annual total (MAT) basis, the GLP-1 market had reached ₹2,492 crore by September. Semaglutide sales stood at ₹113.3 crore during the month, while tirzepatide remained ahead at ₹165.6 crore. Together, the two molecules accounted for nearly 97%



of the GLP-1 market.

Pharmarack’s analysis highlights that the biggest change is taking place within semaglutide. Products launched in 2026, which include mostly generic drugs launched following the expiry of Novo Nordisk’s semaglutide patent, accounted for ₹66.7 crore, or 58.8% of September’s semaglutide sales.

Torrent Pharmaceuticals’ Semalix led this group with sales of ₹13 crore, followed by its Sembolic at ₹6.7 crore and Eris Lifesciences’ Sundae at ₹

6.3 crore. “The fresh growth is being driven by generic versions of semaglutide. Products launched before 2026, including the innovator brands, have seen a decline in sales. Since May, we are also seeing strong demand for anti-obesity drugs in tier-II and tier-III markets,” said Sheetal Sapale, vice-president (commercial) at Pharmarack.

Eli Lilly’s tirzepatide continues to lead the anti-obesity market. It accounted for 57.5% of September sales, compared with 39.4% for semaglutide. Mounjaro, the leading GLP-1 brand, remained the country’s top-selling drug, with September sales of ₹133.7 crore. Its sales value jumped 15.2% from a year earlier, even as volumes fell 43.9%. The shift towards generics has not been uniform across the segment. Pharmarack’s June analysis showed that while 31 generic semaglutide brands accounted for 82% of injectable unit sales, the pace of incremental generic sales had begun to slow.

FROM THE FRONT PAGE

US suspends H-1B visa...

“IF YOU DO the math, for every worker that Microsoft laid off, they replaced that worker with one and a half foreign indentured servants,” Vance said while announcing the decision.

The move marks a drastic attempt by the Donald Trump administration to crack down on the H-1B programme for high-skilled employees, which has historically been mainly used by tech companies.

Large proportion of H-1B workers have historically been Indian techies.

Sonderling stated that since 2009, the mentioned companies had requested approximately 3 million foreign workers and received over 230,000 H-1B visa approvals and more than 100,000 permanent labour certifications.

The H-1B programme has long been targeted by the current US administration with widespread efforts to halt it. Earlier in August, the US Department of Homeland Security had proposed a steep \$103,265 fee charge on new H-1B petitions.

This was just months after the Trump administration had tried to push the hike in fees earlier but failed after a federal court struck the proposal down.

India explores power corridor to Singapore

SAURAY ANAND
New Delhi, October 8

INDIA IS EXPLORING a 3,000-km land-based transmission corridor to Singapore with a capacity to carry 2,000 MW of clean electricity, potentially opening a new route for cross-border power trade between South and Southeast Asia.

One option under consideration would connect Imphal to Singapore through Myanmar, Thailand and Malaysia, Minister of State for Power Shripad Yesso Naik said at the 20th East Asia Summit Energy Ministers’ Meeting in Manila.

“India and Singapore are exploring options for a proposed 2,000 MW cross-border power interconnection,” Naik said.

“The proposed interconnection has the potential to facilitate reliable cross-border electricity trade, support clean energy integration and strengthen regional energy security,” he added.

The plan assumes significance as Singapore’s Energy Market Authority has set a target to import around 6 GW of low-carbon electricity by 2035.

Naik stressed the need for cooperation under the ASEAN India Plan of Action 2026-2030, covering the ASEAN Power Grid, regional transmis-



sion, multilateral electricity trade, clean energy and energy security. India also offered to share its experience in large-scale renewable deployment, grid integration, transmission planning, energy storage and green hydrogen.

The proposed corridor also aligns with the One Sun One World One Grid (OSOWOG) initiative. India, Saudi Arabia, the UAE and Singapore are at various stages of planning a mega-grid infrastructure aimed at enabling renewable power trade from Southeast Asia to Europe through West Asia. Separately, India, Nepal, Bhutan, Bangladesh and Sri Lanka are seeking a consultant to prepare a regional transmission master plan to strengthen cross-border electricity trade, improve grid reliability and develop a regional power market platform.

This is only an advertisement for information purposes and not for publication, distribution, or release directly or indirectly outside India. This is not an announcement for the Offer Document.



CENTURY EXTRUSIONS LIMITED
Engineered with Excellence

CENTURY EXTRUSIONS LIMITED

Century Extrusions Limited ("Company" or "Issuer") was incorporated as a public limited company under the Companies Act, 1956 and a certificate of incorporation dated February 02, 1988, was issued to our Company by the Registrar of Companies, West Bengal at Calcutta. Our Company received the certificate of commencement of business from the Registrar of Companies, West Bengal at Calcutta on April 01, 1990. For further details in relation to changes in the registered office of our Company, see "General Information" on page 48 of the Letter of Offer.

Registered Office: 113, Park Street, Second Floor, 'N' Block Kolkata- 700016

Corporate Office: Mohan Cooperative Industrial Est. JDKD Corporate Park, A-23, Main Mathura Rd, New Delhi-110044

Contact Person: Rajan Singh, Company Secretary and Compliance Officer

Contact No.: (033) 22291012/1291 | E-mail: secretary@centuryextrusions.com | Website: www.centuryextrusions.com

Corporate Identity Number: L27203WB1988PLC043705

PROMOTERS OF OUR COMPANY: VIKRAM JHUNJHUNWALA, SITA DEVI JHUNJHUNWALA, SHIVANSHU JHUNJHUNWALA, MADHAB PRASAD JHUNJHUNWALA (HUF), MOULSHREE JHUNJHUNWALA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF CENTURY EXTRUSIONS LIMITED ONLY

WE HEREBY CONFIRM THAT NONE OF OUR PROMOTERS OR DIRECTORS IS A WILFUL DEFAULTER AS ON DATE OF THE LETTER OF OFFER

ISSUE OF UP TO 3,00,00,000* PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH OF OUR COMPANY ("RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ 15 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 14 PER RIGHTS EQUITY SHARE) AGGREGATING UP TO ₹ 4,500 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 3 (THREE) RIGHTS EQUITY SHARES FOR EVERY 8 (EIGHT) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY ON THE RECORD DATE, THAT IS, ON SEPTEMBER 15, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 78 OF THE LETTER OF OFFER ("LOF").

*** Assuming full subscription in the Issue, subject to finalization of Basis of Allotment.**

RIGHTS ISSUE PERIOD EXTENDED	
ISSUE CLOSING DATE (OLD)	ISSUE CLOSES DATE (NEW)
WEDNESDAY, OCTOBER 14, 2026	WEDNESDAY, OCTOBER 21, 2026

INDICATIVE TIMETABLE	
LAST DATE FOR ON MARKET RENUNCIATION* OF RIGHTS ENTITLEMENTS	Thursday, October 08, 2026
ISSUE CLOSING DATE*	Wednesday, October 21, 2026
FINALIZATION OF BASIS OF ALLOTMENT (ON OR ABOUT)	Thursday, October 22, 2026
DATE OF ALLOTMENT (ON OR ABOUT)	Thursday, October 22, 2026
DATE OF CREDIT OF RIGHTS EQUITY SHARES (ON OR ABOUT)	Friday, October 23, 2026
DATE OF LISTING (ON OR ABOUT)	Monday, October 26, 2026

***Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncers on or prior to the Issue Closing Date. Therefore, all the references to the issue Closing Date made in the Letter of Offer ("LOF") and Composite Application Form ("CAF") each dated September 08, 2026 and Issue opening Advertisement published on September 19, 2026 shall be October 21, 2026. All other terms and conditions mentioned in the LOF, Application form and Issue Advertisement continue to be applicable.**

Simple, Safe, Smart way of Application - Make use of it!!!

ASBA* ***Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below**

This is to inform the shareholders of the Company that the date of closure of the Rights Issue, which opened on Wednesday, September 23, 2026, and was scheduled to close on Wednesday, October 14, 2026; subsequently, the Company has decided to extend the Issue Closing Date from Wednesday, October 14, 2026 to Wednesday, October 21, 2026, in order to provide opportunity to shareholders to exercise their rights in the Rights Issue.

Accordingly, the last date for submission of the duly filled in Application Form (along with amount payable on Application) is Wednesday, October 21, 2026. Equity Shareholders of the Company who are entitled to apply for the Rights Issue as mentioned above are requested to take note of the Issue Closing Date as Wednesday, October 21, 2026.

Further, the Minimum Subscription clause mentioned at page no. 52 of the LOF shall be read as follows :

"The objects of the issue involves (i) Repayment/Pre-payment, in full or part, of certain unsecured borrowings availed by the Company (ii) To augment the existing and incremental working capital requirement of our manufacturing facility situated at Khargapur; and (iii) General Corporate Purposes"

Our Promoters and Promoter Group have vide letter dated March 26, 2026 informed that they will (i) fully subscribe to their entitlements arising out of the proposed rights issue, (ii) subscribe to the Rights Entitlements which may be renounced in their favour by any other member of the Promoter Group, except to the extent of renunciation by the Promoters for the purpose of complying with minimum public shareholding norms prescribed under the Securities Contract Regulation Rules and (iii) may apply and subscribe either fully or partially to additional right equity shares if any which remain unsubscribed in the Rights Issue, if so deemed fit, subject to such subscription being in compliance with the minimum public shareholding requirements prescribed under the Securities Contracts (Regulation) Rules, 1957, the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Accordingly, the minimum subscription criteria provided under Regulation 86 (1) of the SEBI ICDR Regulations shall not apply to this Issue."

Facilities for application in the Issue: In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI Rights Issue Circular, all Investors desiring to make an Application in this issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, please see "Making of an Application through the ASBA Process" on pages 81 the Letter of Offer.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, PLEASE REFER TO "ALLOTMENT ADVICE OR REFUND ORDERS" UNBLOCKING OF ASBA ACCOUNTS" BEGINNING ON PAGE 98 OF THE LETTER OF OFFER.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN DEMATERIALIZED FORM.

PLEASE NOTE THAT THE RIGHTS ENTITLEMENTS WHICH ARE NEITHER RENOUNCED NOR SUBSCRIBED BY THE INVESTORS ON OR BEFORE THE ISSUE CLOSING DATE SHALL LAPSE AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE.

There is no change in the Letter of Offer dated September 08, 2026, the Rights Entitlement Letter and the Application Form except for modification in the Issue Closing Date and resultant change in indicative timetable of post issue activities on account of extension of the Issue Closing Date

For Century Extrusions Limited
Sd/-
Date: October 08, 2026
Place: Kolkata
Rajan Singh
Company Secretary & Compliance Officer

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated September 08, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com. Company at www.centuryextrusions.com, website of the Registrar at www.in.mps.mufg.com. Potential Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 22 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

RAJA BAHADUR INTERNATIONAL LIMITED
CIN No.: L17120MH1926PLC001273
Regd. Office: Hamam House, 3rd Floor, Ambalal Doshi Marg, Fort, Mumbai - 400001.
Tel No.: 022 22654278

Email ID: investor@rajabahadur.com, **website:** www.rajabahadur.com

NOTICE FOR SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SECURITIES

This is to inform you that the Securities and Exchange Board of India ("SEBI") vide circular no. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30 2026 has decided to open a special window for Transfer and Dematerialisation of Physical Securities, which were sold/purchased prior to April 01, 2019. This special window shall be open for a period of one year from February 05, 2026 to February 04, 2027. The special window shall also be available for such transfer requests which were submitted earlier and were rejected/returned/not attended to due to deficiency in the documents/process/or otherwise.

The concerned investors are requested to lodge the transfer request of physical shares, to our Registrar and Share Transfer Agents (RTA), Satellite Corporate Services Pvt. Ltd. Website : www.satellitecorporate.com within the above-mentioned timelines. Relevant investor(s) are encouraged to take advantage of this one-time window.

For Raja Bahadur International Limited
Sd/-
Tanaya Daryanani
Company Secretary and Compliance Officer
ICSI Membership No. ACS : 37181

Date: 08.10.2026

Panacea Biotech
(CIN: L33117PB1984PLC022350)
Regd. Office: Ambala-Chandigarh Highway, Lahu - 140 501, Punjab, India
Corp. Office: B-1 Extn./A-27, Mohan Co-operative Indl. Estate, Mathura Road, New Delhi - 110044, India
Website: www.panaceabiotech.com E-mail: companysec@panaceabiotech.com Tel: +91 11 41679000

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SHARES

Dear Shareholders,

In furtherance to our earlier communications, we hereby reiterate that pursuant to the SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026 ("SEBI Circular"), you are requested to please note that a special window to facilitate lodgement / re-lodgement of transfer requests w.r.t. physical shares of Panacea Biotech Limited ("the Company") will remain open upto **February 04, 2027**.

This facility is restricted to the shareholders holding shares in physical form, who sold / purchased shares of the Company prior to April 01, 2019, and:

(a) had not lodged the shares for transfer; or

(b) had lodged the shares for transfer, but the same were rejected, returned, or not attended to due to deficiencies in the documentation.

Eligible shareholders are requested to submit their request for transfer and dematerialisation of shares along with original share certificate(s) and other requisite documents as specified in the aforesaid SEBI Circular to the Company's Registrar and Share Transfer Agent (RTA) viz. M/s Skyline Financial Services Pvt. Ltd. at 1st Floor, D-153/A, Pocket D, Okhla Phase I, Okhla Industrial Estate, New Delhi - 110020; Email id: compliance@skylinertn.com, Tel. No. 011-4405193-97, within the stipulated period. For further details, investors may refer to the SEBI Circular available at: <https://tinyurl.com/29ab3727>.

Note: All the shareholders are requested to update their email-id(s) with Company / RTA / Depository Participants.

For Panacea Biotech Limited
Sd/-
Ankit Jain
Date : October 08, 2026
Place : New Delhi
General Manager - Legal & Company Secretary
Membership No. A29499

India backs US-led initiative against 'excess capacity'

FE BUREAU
New Delhi, October 8

INDIA HAS JOINED a US-led initiative to tackle “structural excess capacity” in manufacturing, a move that could draw scrutiny given its own rapid expansion in sectors such as solar modules, steel and petrochemicals, some of which are already under the Trump administration’s trade lens.

The initiative seeks to address concerns that excess manufacturing capacity can distort global trade by fuelling overproduction, depressing prices and displacing domestic industries through state-subsidised dumping.

India is among 15 economies that have signed a joint ministerial statement unveiled by the US Trade Representative (USTR) to address structural excess capacity and production.

The initiative will initially cover automobiles and electric vehicles, batteries, chemicals, foundational semiconductors and solar panels, with participating economies setting up sectoral platforms to exchange information and explore coordinated action.

The move comes nearly seven months after USTR launched a Section 301 investigation into structural excess capacity across 16 economies, including India, the European Union, Japan, Mexico and South Korea. The five are now both subjects of the probe and signatories to the new initiative.

USTR has raised concerns about expanding capacity and potential export-driven oversupply in solar modules, steel and petrochemicals, citing Indian solar-module capacity as nearly three times annual domestic demand. The deadline for its final Section 301 findings is March 11, 2027. The joint statement calls for countries to eliminate structural excess capacity, including by ending non-market policies and practices that distort markets. It says excess capacity can lead to overproduction, price distortions, concentration of production and weaker competition.

The Global Trade Research Initiative (GTRI) founder Ajay Srivastava said India was now “joining Washington in tackling the very issue for which its own manufacturing is under American investigation”.

US-LED PUSH

■ 15 economies have signed joint ministerial statement

■ Initial focus: autos & EVs, batteries, chemicals, foundational semiconductors

■ Initiative aims to curb overproduction, price distortions, state-subsidised dumping



■ Comes amid Section 301 probe by US into excess capacity across 16 economies

■ India is both under probe and signatory to new initiative

WTO raises global trade forecast for 2026 to 3.9%

FE BUREAU
New Delhi, October 8

THE WEST ASIA conflict has disrupted energy supplies and shipping routes but has so far failed to derail global merchandise trade, prompting the World Trade Organization (WTO) to sharply raise its forecast for 2026 trade growth to 3.9% from 1.9% in its March outlook.

The latest Global Trade Outlook and Statistics, released Thursday, marks a significant turnaround from the WTO’s earlier assessment. The organisation had cut its 2026 merchandise trade forecast to 1.9% in March as the conflict raised the prospect of an oil shock and wider disruption. It now expects global merchandise trade volume to grow another 4.1% in 2027.

The stronger outlook follows 3.5% growth in merchandise trade in the first half of 2026, despite the conflict. Supply chains adapted by switching suppliers and rerouting trade through alternative ports and corridors. West Asia crude oil exports fell about 24% and LNG exports 47% during the period, but increased shipments from other suppliers limited the decline in global exports to around 6% for crude and 1% for LNG. Global container throughput rose 3.9% through July.



The biggest support came from the boom in artificial intelligence investment. Semiconductors, servers and other AI-enabling goods accounted for 47% of global merchandise trade growth in the first half, with trade in these products rising 67% year-on-year.

The conflict has had a more visible impact on services trade.

The WTO cut its 2026 forecast for commercial services trade growth to 3.3% from 4.8%, before projecting a rebound to 6.4% in 2027. Transport services have been hit by rerouted shipping and higher freight costs, while international travel has weakened.

International tourist arrivals fell 0.8% year-on-year in the second quarter and were only 0.4% higher in the first half. In contrast, digitally delivered services remained resilient, with computer services exports rising 1.8% in the first quarter and an estimated 12% in the second.

SC orders pharma marketing review

MANU KAUSHIK
New Delhi, October 8

THE SUPREME COURT has directed the Centre to set up a panel to review unethical pharma marketing practices and assess whether the existing regulatory framework is adequate. The panel will also examine mechanisms for monitoring, transparency and enforcement.

The move comes after the court found that the existing framework warranted closer examination, particularly its effectiveness in preventing unethical practices. The panel will identify gaps and recommend an appropriate statutory or regulatory framework to the government.

The government has two weeks to constitute the panel. It will give petitioners, intervenors and other stakeholders a reasonable opportunity to

submit their views and concerns. The panel may also seek inputs from technical, professional and domain experts.

It has been given two months from its first meeting to complete the exercise and submit its recommendations. The government will then consider the recommendations and take a decision at the earliest. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 will continue to govern pharma marketing practices in the interim, according to the government’s submission. While the court did not make the UCPMP statutory, it said choosing the appropriate statutory or regulatory framework falls primarily within the central government’s domain.

The order noted that the government had already held consultations with industry bodies.

Prices of 110 anti-cancer drugs to fall sharply

MANU KAUSHIK
New Delhi, October 8

THE GOVERNMENT IS set to cap trade margins at 30% on 110 non-scheduled anti-cancer drugs, including 35 patented medicines, sources in the Department of Pharmaceuticals (DoP) told FE. The move could make these high-priced medicines more affordable to consumers.

The government estimates that the cap could cut the maximum retail prices (MRPs) of these drugs by up to 70% and save patients an estimated ₹2,500 crore annually. The tighter margin ceiling is also likely to pressure retailers, hospital chains and pharma companies that earn higher margins on these drugs.

“These non-scheduled drugs were not under any caps before. A committee under the Director General of Health Services (DGHS) will examine and finalise the list of medicines to be covered. The move will cover generics, patented, imported and locally-produced drugs,” the DoP official said.

Non-scheduled drugs are medicines whose prices are not directly fixed by the government. Scheduled drugs, in contrast, are subject to government-controlled price limits under the Drugs (Prices Con-

BIG RELIEF



■ List includes 35 patented medicines

■ Govt estimates MRPs could fall by up to

70%

■ Patients could save an estimated ₹2,500 cr annually

■ Cap will cover generic, patented, imported, locally produced drugs

control) Order, 2013 (DPCO). The scheduled list is based on medicines included in the National List of Essential Medicines (NLEM).

According to the official, the government plans to complete the exercise within 10 days.

The announcement comes as the Supreme Court is examining the issue of high medicine mark-ups.

During a recent hearing, the court questioned why a cancer drug supplied to a retailer for around ₹2,700 had an MRP of ₹27,000 – a ten-fold difference. The bench also questioned whether a uniform margin should apply across medicines and asked the central government to examine the issue. The matter is scheduled for further hearing on October 12.

A pharma association official said the proposal would limit retailers’ margins by restricting the difference between the price paid by the retailer and the MRP to 30%. “This cap will be applicable on the retailers’ margins. The difference between PTR and MRP cannot be more than 30% now.

“There’s already a 16% cap on trade margins on the scheduled drugs across the board. The move is likely to affect retailers, hospital chains and pharma companies, especially those who work on high margins,” he said.

Under the existing framework, the scheduled drugs are subject to government-regulated trade margins when their ceiling prices are fixed.

GLP-1 mkt value jumps 72% on new products

MANU KAUSHIK
New Delhi, October 8

THE ANTI-OBESITY drug GLP-1 market grew 72% in sales value year-on-year in September 2026, even as the number of units sold fell 10%, according to the latest data from healthcare research firm Pharmarack. The growth was driven largely by new products, while prices remained broadly unchanged. The sharp divergence between value and volume growth points to a significant shift in the market’s composition.

According to the report, the broader anti-obesity drug market stood at ₹287.9 crore in September, up 5.8% from ₹272.1 crore in August. On a moving annual total (MAT) basis, the GLP-1 market had reached ₹2,492 crore by September. Semaglutide sales stood at ₹113.3 crore during the month, while tirzepatide remained ahead at ₹165.6 crore. Together, the two molecules accounted for nearly 97%



of the GLP-1 market.

Pharmarack’s analysis highlights that the biggest change is taking place within semaglutide. Products launched in 2026, which include mostly generic drugs launched following the expiry of Novo Nordisk’s semaglutide patent, accounted for ₹66.7 crore, or 58.8% of September’s semaglutide sales.

Torrent Pharmaceuticals’ Semalix led this group with sales of ₹13 crore, followed by its Sembolic at ₹6.7 crore and Eris Lifesciences’ Sundae at ₹

6.3 crore. “The fresh growth is being driven by generic versions of semaglutide. Products launched before 2026, including the innovator brands, have seen a decline in sales. Since May, we are also seeing strong demand for anti-obesity drugs in tier-II and tier-III markets,” said Sheetal Sapale, vice-president (commercial) at Pharmarack.

Eli Lilly’s tirzepatide continues to lead the anti-obesity market. It accounted for 57.5% of September sales, compared with 39.4% for semaglutide. Mounjaro, the leading GLP-1 brand, remained the country’s top-selling drug, with September sales of ₹133.7 crore. Its sales value jumped 15.2% from a year earlier, even as volumes fell 43.9%. The shift towards generics has not been uniform across the segment. Pharmarack’s June analysis showed that while 31 generic semaglutide brands accounted for 82% of injectable unit sales, the pace of incremental generic sales had begun to slow.

FROM THE FRONT PAGE

US suspends H-1B visa...

“IF YOU DO the math, for every worker that Microsoft laid off, they replaced that worker with one and a half foreign indentured servants,” Vance said while announcing the decision.

The move marks a drastic attempt by the Donald Trump administration to crack down on the H-1B programme for high-skilled employees, which has historically been mainly used by tech companies.

Large proportion of H-1B workers have historically been Indian techies.

Sonderling stated that since 2009, the mentioned companies had requested approximately 3 million foreign workers and received over 230,000 H-1B visa approvals and more than 100,000 permanent labour certifications.

The H-1B programme has long been targeted by the current US administration with widespread efforts to halt it. Earlier in August, the US Department of Homeland Security had proposed a steep \$103,265 fee charge on new H-1B petitions.

This was just months after the Trump administration had tried to push the hike in fees earlier but failed after a federal court struck the proposal down.

India explores power corridor to Singapore

SAURAV ANAND
New Delhi, October 8

INDIA IS EXPLORING a 3,000-km land-based transmission corridor to Singapore with a capacity to carry 2,000 MW of clean electricity, potentially opening a new route for cross-border power trade between South and Southeast Asia.

One option under consideration would connect Imphal to Singapore through Myanmar, Thailand and Malaysia, Minister of State for Power Shripad Yesso Naik said at the 20th East Asia Summit Energy Ministers’ Meeting in Manila.

“India and Singapore are exploring options for a proposed 2,000 MW cross-border power interconnection,” Naik said.

“The proposed interconnection has the potential to facilitate reliable cross-border electricity trade, support clean energy integration and strengthen regional energy security,” he added.

The plan assumes significance as Singapore’s Energy Market Authority has set a target to import around 6 GW of low-carbon electricity by 2035.

Naik stressed the need for cooperation under the ASEAN-India Plan of Action 2026-2030, covering the ASEAN Power Grid, regional transmis-



sion, multilateral electricity trade, clean energy and energy security. India also offered to share its experience in large-scale renewable deployment, grid integration, transmission planning, energy storage and green hydrogen.

The proposed corridor also aligns with the One Sun One World One Grid (OSOWOG) initiative. India, Saudi Arabia, the UAE and Singapore are at various stages of planning a mega-grid infrastructure aimed at enabling renewable power trade from Southeast Asia to Europe through West Asia. Separately, India, Nepal, Bhutan, Bangladesh and Sri Lanka are seeking a consultant to prepare a regional transmission master plan to strengthen cross-border electricity trade, improve grid reliability and develop a regional power market platform.

This is only an advertisement for information purposes and not for publication, distribution, or release directly or indirectly outside India. This is not an announcement for the Offer Document.

Please scan this QR code to view the Letter of Offer

CENTURY EXTRUSIONS LIMITED
Engineered with Excellence

CENTURY EXTRUSIONS LIMITED

Century Extrusions Limited ("Company" or "Issuer") was incorporated as a public limited company under the Companies Act, 1956 and a certificate of incorporation dated February 02, 1988, was issued to our Company by the Registrar of Companies, West Bengal at Calcutta. Our Company received the certificate of commencement of business from the Registrar of Companies, West Bengal at Calcutta on April 01, 1990. For further details in relation to changes in the registered office of our Company, see "General Information" on page 48 of the Letter of Offer.

Registered Office: 113, Park Street, Second Floor, 'N' Block Kolkata- 700016
Corporate Office: Mohan Cooperative Industrial Est. JDKN Corporate Park, A-23, Main Mathura Rd, New Delhi-110044
Contact Person: Rajan Singh, Company Secretary and Compliance Officer
Contact No.: (033) 22291012/1291 | E-mail: secretary@centuryextrusions.com | Website: www.centuryextrusions.com
Corporate Identity Number: L27203WB1988PLC043705

PROMOTERS OF OUR COMPANY: VIKRAM JHUNJHUNWALA, SITA DEVI JHUNJHUNWALA, SHIVANSHU JHUNJHUNWALA, MADHAB PRASAD JHUNJHUNWALA (HUF), MOULSHREE JHUNJHUNWALA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF CENTURY EXTRUSIONS LIMITED ONLY

WE HEREBY CONFIRM THAT NONE OF OUR PROMOTERS OR DIRECTORS IS A WILFUL DEFAULTER AS ON DATE OF THE LETTER OF OFFER

ISSUE OF UP TO 3,00,00,000* PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH OF OUR COMPANY ("RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ 15 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 14 PER RIGHTS EQUITY SHARE) AGGREGATING UP TO ₹ 4,500 LAKHS* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 3 (THREE) RIGHTS EQUITY SHARES FOR EVERY 8 (EIGHT) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY ON THE RECORD DATE, THAT IS, ON SEPTEMBER 15, 2026 ("RECORD DATE") THE "ISSUE"). FOR FURTHER DETAILS, PLEASE REFER TO THE SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 78 OF THE LETTER OF OFFER ("LOF").

** Assuming full subscription in the Issue, subject to finalization of Basis of Allotment.*

RIGHTS ISSUE PERIOD EXTENDED	
ISSUE CLOSING DATE (OLD)	ISSUE CLOSES DATE (NEW)
WEDNESDAY, OCTOBER 14, 2026	WEDNESDAY, OCTOBER 21, 2026

INDICATIVE TIMETABLE

LAST DATE FOR ON MARKET RENUNCIATION* OF RIGHTS ENTITLEMENTS	Thursday, October 08, 2026
ISSUE CLOSING DATE* <td>Wednesday, October 21, 2026</td>	Wednesday, October 21, 2026
FINALIZATION OF BASIS OF ALLOTMENT (ON OR ABOUT) <td>Thursday, October 22, 2026</td>	Thursday, October 22, 2026
DATE OF ALLOTMENT (ON OR ABOUT) <td>Thursday, October 22, 2026</td>	Thursday, October 22, 2026
DATE OF CREDIT OF RIGHTS EQUITY SHARES (ON OR ABOUT) <td>Friday, October 23, 2026</td>	Friday, October 23, 2026
DATE OF LISTING (ON OR ABOUT) <td>Monday, October 26, 2026</td>	Monday, October 26, 2026

**Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renunciator on or prior to the Issue Closing Date. Therefore, all the references to the issue Closing Date made in the Letter of Offer ("LOF") and Composite Application Form ("CAF") each dated September 08, 2026 and Issue opening Advertisement published on September 19, 2026 shall be October 21, 2026. All other terms and conditions mentioned in the LOF, Application form and Issue Advertisement continue to be applicable.*

ASBA*

Simple, Safe, Smart way of Application - Make use of it!!!

***Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details read section on ASBA below**

This is to inform the shareholders of the Company that the date of closure of the Rights Issue, which opened on Wednesday, September 23, 2026, and was scheduled to close on Wednesday, October 14, 2026; subsequently, the Company has decided to extend the Issue Closing Date from Wednesday, October 14, 2026 to Wednesday, October 21, 2026, in order to provide opportunity to shareholders to exercise their rights in the Rights Issue.

Accordingly, the last date for submission of the duly filled in Application Form (along with amount payable on Application) is Wednesday, October 21, 2026. Equity Shareholders of the Company who are entitled to apply for the Rights Issue as mentioned above are requested to take note of the issue Closing Date as Wednesday, October 21, 2026.

Further, the Minimum Subscription clause mentioned at page no. 52 of the LOF shall be read as follows :

"The objects of the issue involves (i) Repayment/Pre-payment, in full or part, of certain unsecured borrowings availed by the Company (ii) To augment the existing and incremental working capital requirement of our manufacturing facility situated at Khargapur; and (iii) General Corporate Purposes"

Our Promoters and Promoter Group have vide letter dated March 26, 2026 informed that they will (i) fully subscribe to their entitlements arising out of the proposed rights issue, (ii) subscribe to the Rights Entitlements which may be renounced in their favour by any other member of the Promoter Group, except to the extent of renunciation by the Promoters for the purpose of complying with minimum public shareholding norms prescribed under the Securities Contract Regulation Rules and (iii) may apply and subscribe either fully or partially to additional right equity shares if any which remain unsubscribed in the Rights Issue, if so deemed fit, subject to such subscription being in compliance with the minimum public shareholding requirements prescribed under the Securities Contracts (Regulation) Rules, 1957, the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Accordingly, the minimum subscription criteria provided under Regulation 86 (1) of the SEBI ICDR Regulations shall not apply to this Issue."

Facilities for application in the Issue: In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI Rights Issue Circular, all Investors desiring to make an Application in this issue are mandatorily required to use the ASBA process. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, please see "Making of an Application through the ASBA Process" on pages 81 the Letter of Offer.

ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM.

PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE. FOR DETAILS, PLEASE REFER TO "ALLOTMENT ADVICE OR REFUND ORDERS" UNBLOCKING OF ASBA ACCOUNTS" BEGINNING ON PAGE 98 OF THE LETTER OF OFFER.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN DEMATERIALIZED FORM.

PLEASE NOTE THAT THE RIGHTS ENTITLEMENTS WHICH ARE NEITHER RENOUNCED NOR SUBSCRIBED BY THE INVESTORS ON OR BEFORE THE ISSUE CLOSING DATE SHALL LAPSE AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE.

There is no change in the Letter of Offer dated September 08, 2026, the Rights Entitlement Letter and the Application Form except for modification in the Issue Closing Date and resultant change in indicative timetable of post issue activities on account of extension of the Issue Closing Date

For Century Extrusions Limited
Sd/-
Date: October 08, 2026
Place: Kolkata

Rajan Singh
Company Secretary & Compliance Officer

Disclaimer: Our Company is proposing, subject to market conditions and other considerations, to make a rights issue of its equity shares, and has filed a Letter of Offer dated September 08, 2026 with the Stock Exchanges. The Letter of Offer is available on the website of the Stock Exchanges, i.e., BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com. Company at www.centuryextrusions.com, website of the Registrar at www.in.mpps.mufg.com. Potential Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section titled "Risk Factors" beginning on page 22 of the Letter of Offer for details of the same. Potential Investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. The LOF does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. The Rights Entitlements and Rights Equity Shares offered in the Issue have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, such Rights Entitlements and Rights Equity Shares are being offered and sold (i) outside of the United States in offshore transactions in reliance upon Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements, under Section 4(a) of the Securities Act.

RAJA BAHADUR INTERNATIONAL LIMITED

CIN No.: L17120MH1926PLC001273

Regd. Office: Hamam House, 3rd Floor, Ambalal Doshi Marg, Fort, Mumbai - 400001.

Tel No.: 022 22654278

Email ID: investor@rajabahadur.com, website: www.rajabahadur.com

NOTICE FOR SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SECURITIES

This is to inform you that the Securities and Exchange Board of India ("SEBI") vide circular no. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30 2026 has decided to open a special window for Transfer and Dematerialisation of Physical Securities, which were sold/purchased prior to April 01, 2019. This special window shall be open for a period of one year from February 05, 2026 to February 04, 2027. The special window shall also be available for such transfer requests which were submitted earlier and were rejected/returned/not attended to due to deficiency in the documents/process/or otherwise.

The concerned investors are requested to lodge the transfer request of physical shares, to our Registrar and Share Transfer Agents (RTA), Satellite Corporate Services Pvt. Ltd. Website : www.satellitecorporate.com within the above-mentioned timelines. Relevant investor(s) are encouraged to take advantage of this one-time window.

For Raja Bahadur International Limited
Sd/-
Tanaya Daryanani
Company Secretary and Compliance Officer
ICSI Membership No. ACS : 37181

Date: 08.10.2026

Panacea Biotech Limited

(CIN: L33117PB1984PLC022350)

Regd. Office: Ambala-Chandigarh Highway, Lahu - 140 501, Punjab, India.

Corp. Office: B-1 Extn/A-27, Mohan Co-operative Indl. Estate, Mathura Road, New Delhi - 110044, India

Website: www.panaceabiotech.com E-mail: companysec@panaceabiotech.com Tel: +91 11 41679000

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SHARES

Dear Shareholders,

In furtherance to our earlier communications, we hereby reiterate that pursuant to the SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/13750/2026 dated January 30, 2026 ("SEBI Circular"), you are requested to please note that a special window to facilitate lodgement /re-lodgement of transfer requests w.r.t. physical shares of Panacea Biotech Limited ("The Company") will remain open upto **February 04, 2027**.

This facility is restricted to the shareholders holding shares in physical form, who sold / purchased shares of the Company prior to April 01, 2019, and:

(a) had not lodged the shares for transfer; or

(b) had lodged the shares for transfer, but the same were rejected, returned, or not attended to due to deficiencies in the documentation.

Eligible shareholders are requested to submit their request for transfer and dematerialisation of shares along with original share certificate(s) and other requisite documents as specified in the aforesaid SEBI Circular to the Company's Registrar and Share Transfer Agent (RTA) viz. M/s Skyline Financial Services Pvt. Ltd. at 1st Floor, D-153/A, Pocket D, Okhla Phase I, Okhla Industrial Estate, New Delhi - 110020. Email id: compliances@skylinertn.com, Tel. No. 011-44045193-97, within the stipulated period.

For further details, investors may refer to the SEBI Circular available at: <https://tinyurl.com/29ab3727>.

Note: All the shareholders are requested to update their email-id(s) with Company / RTA / Depository Participants.

For Panacea Biotech Limited
Sd/-
Ankit Jain
General Manager - Legal & Company Secretary
Membership No. A29499

Date : October 08, 2026
Place : New Delhi

epaper.financialexpress.com

epaper.financialexpress.com

